Multiple Sclerosis Financial Planning: SSDI Strategy, DMT Costs, and Special Needs Trust Planning

Nearly 1 million Americans live with multiple sclerosis, and approximately 200 new cases are diagnosed every week — most of them working-age adults between 20 and 50.¹ That demographic distinction shapes everything about MS financial planning. Unlike most conditions covered on this site — where parents plan for a child with a disability — MS financial planning is often about a working adult managing a transition from full employment to partial or no employment, while simultaneously trying to preserve benefits, protect assets, and plan for a future care trajectory that can vary from mild inconvenience to total dependency. This guide addresses what that planning requires that most general advisors don't know to ask.

Why MS financial planning is different

Special needs financial planning typically focuses on trusts, SSI, and Medicaid preservation for families caring for a disabled dependent. All of that applies to MS — but the dominant scenario is different:

• MS is acquired in working age. Most people with MS have years or decades of work history before diagnosis. That means they likely have Social Security work credits, access to employer-sponsored insurance, and their own savings — and the financial plan must account for the transition from financial independence to disability benefit dependency, not just the management of a disability that was present from birth or childhood.
• SSDI, not just SSI, is the primary disability benefit. Unlike most childhood-onset disabilities where SSI is the primary cash support, MS patients who worked before their diagnosis will typically qualify for Social Security Disability Insurance (SSDI) at a benefit level based on their earnings history. SSDI benefits can range from a few hundred dollars to over $3,500/month depending on lifetime earnings — often far exceeding the SSI Federal Benefit Rate of $994/month in 2026.²
• Disease-modifying therapies create an immediate, large coverage gap problem. MS DMTs cost $60,000–$150,000+ per year at list price. Before Medicare kicks in — which requires a 24-month waiting period after SSDI begins — the person with MS must bridge drug coverage through COBRA, a marketplace plan, or other means. This gap is predictable, expensive, and often missed in financial planning until it's already a cash crisis.
• The planning horizon is highly variable. Relapsing-remitting MS (RRMS) can plateau for decades with minimal functional impact. Primary progressive MS (PPMS) follows a steadily worsening trajectory from onset. The financial plan must account for both the optimistic and pessimistic scenarios — not as speculation, but as a structured range that informs insurance coverage, SNT sizing, and savings targets.
• Life insurance and disability insurance close as the disease progresses. In early RRMS, coverage may still be available — at rated premiums, but available. By the time someone with MS is applying for SSDI, those insurance options are largely gone. The planning window is early, when it feels least urgent.

Types of MS and their financial planning profiles

MS takes several forms, each with a distinct planning trajectory:

Disease-modifying therapy costs and the coverage gap problem

MS disease-modifying therapies are among the most expensive chronically-used medications in any condition category. Understanding how they're covered — and where coverage fails — is central to MS financial planning.

What DMTs cost

Ocrevus (ocrelizumab), the most widely prescribed high-efficacy DMT for both RRMS and PPMS, carries a list price of approximately $65,000 per year — but when combined with infusion facility fees, total annual medical costs for Ocrevus have been measured at $110,000–$125,000 in the year of initiation and $106,000–$110,000 in subsequent years.³ Tysabri (natalizumab), another high-efficacy infusion therapy, runs in a similar total cost range. Oral DMTs like Zeposia, Mayzent, and Vumerity carry list prices of $80,000–$100,000+ per year.

For patients with good insurance coverage, out-of-pocket costs are manageable — pharmaceutical assistance programs from manufacturers and copay cards reduce patient exposure significantly for commercially insured patients. The cost problem concentrates in two scenarios: (1) loss of employer insurance after leaving work, and (2) the 24-month Medicare waiting period after SSDI approval.

Medicare coverage for MS DMTs: Part B vs Part D

How a DMT is administered determines which Medicare benefit covers it — and that distinction matters for out-of-pocket costs:

• Infusion DMTs (Ocrevus, Tysabri, Lemtrada) are administered by a healthcare provider and covered under Medicare Part B (medical insurance). Part B pays 80% after the deductible; the remaining 20% with no cap is your responsibility. For Ocrevus at $65K/year, that's approximately $13,000/year in coinsurance with standard Medicare — or close to zero if you have a Medigap supplemental plan that covers Part B coinsurance.
• Oral and self-injectable DMTs (Kesimpta, Vumerity, Zeposia, Mayzent, Tecfidera) are covered under Medicare Part D (drug benefit). Starting in 2026, Medicare Part D out-of-pocket costs are capped at $2,100 per year under the Inflation Reduction Act — a significant change that makes oral DMTs substantially more affordable for MS patients on Medicare.⁴

Bottom line: MS patients on Medicare who use oral DMTs benefit enormously from the $2,100 Part D cap. Patients on infusion DMTs need Medigap coverage to manage Part B coinsurance. A specialist advisor will model the cost structure based on the specific DMT regimen.

The 24-month Medicare waiting period: the acute financial problem

When someone with MS stops working and files for SSDI, they face two mandatory waiting periods before Medicare coverage begins:

1. 5-month SSDI waiting period: SSA does not pay SSDI benefits for the first 5 months after the established onset date of disability. If onset is established as November 1, 2025, the first SSDI payment covers May 2026.²
2. 24-month Medicare waiting period: Medicare eligibility begins 24 months after the first month of SSDI entitlement — meaning it starts approximately 29 months after the established onset date. Using the same example: Medicare begins around October 2028.

The resulting gap between leaving employer coverage and reaching Medicare can extend to 2.5+ years — during which the person with MS must maintain coverage for DMTs and all other medical costs out of pocket or through alternative plans. Options:

The financial plan for someone approaching a transition to SSDI should model this gap explicitly: estimate monthly COBRA premiums, assess the 29-month COBRA disability extension, and identify which manufacturer assistance programs apply to the current DMT regimen. Failure to plan for this gap results in unmanageable out-of-pocket costs or — worse — interrupting DMT therapy, which risks rebound inflammatory activity in some treatments.

SSDI: qualifying and timing

Most adults with MS who worked before diagnosis will pursue SSDI rather than SSI. Key aspects of qualification:

SSA Blue Book Listing 11.09

MS is evaluated under SSA Neurological Listing 11.09, which has two pathways:⁵

• 11.09A: Disorganization of motor function in two extremities — both lower extremities, both upper extremities, or one upper and one lower — causing an extreme limitation in the ability to stand up from a seated position, maintain balance while standing or walking, or use the upper extremities to independently perform work-related activities.
• 11.09B: Marked limitation in physical functioning AND a marked limitation in one of: (1) understanding, remembering, or applying information; (2) interacting with others; (3) concentrating, persisting, or maintaining pace; or (4) adapting or managing oneself.

MS that doesn't meet either pathway can still qualify under the residual functional capacity (RFC) assessment — SSA considers whether the combined effects of fatigue, heat sensitivity (Uhthoff's phenomenon), cognitive symptoms, and physical limitations prevent sustained full-time work. The episodic nature of MS means RFC evidence should document function on both good days and bad days, not just at a single snapshot examination.

SSDI timing strategy

The SSDI filing decision is not binary. Key timing considerations:

• File when you can no longer consistently work, not just during a relapse. SSA evaluates sustained work capacity. Filing during a relapse and withdrawing when you recover creates a complex claim history. File when the pattern of inability to work consistently has become clear.
• The onset date matters for the Medicare timeline. SSA establishes an "alleged onset date" — the date you stopped being able to work. A documented earlier onset date (supported by medical records, employer records, and neurologist notes about progressive functional decline) can accelerate the Medicare timeline. An experienced SSDI attorney or advocate is worth consulting to establish the earliest defensible onset date.
• Trial Work Period (TWP): Once on SSDI, you have a 9-month Trial Work Period (TWP) to attempt return to work without immediately losing benefits. Months of earnings above $1,210/month in 2026 count toward the TWP. After the TWP, Substantial Gainful Activity (SGA) — earnings above $1,690/month in 2026 — would end benefits. Many MS patients in remission benefit from the TWP to test whether they can return to work.²

Life insurance: the window is early

Life insurance for a person with MS becomes progressively harder to obtain as the disease advances. Early RRMS patients — particularly those who are well-controlled on DMTs and have minimal EDSS progression — may still qualify for individual life insurance at rated (higher) premiums. Underwriters look at disease type, treatment, EDSS score, relapse history, and cognitive involvement. A specialized broker who works with impaired-risk life insurance can identify carriers with the most favorable MS underwriting standards.

Why does this matter for SNT planning? Two scenarios:

1. Parents planning for an adult child with MS may want a survivorship (second-to-die) life insurance policy on themselves to fund a third-party SNT at their deaths — the standard SNT funding model.
2. The person with MS themselves, if they have dependents, may want life insurance before their own insurability closes. Term insurance may remain available longer than permanent insurance, but term doesn't serve as an SNT funding vehicle for a long-horizon trust.

In both cases: apply early. The conversation about life insurance should happen at or near diagnosis, not when disability has progressed to the point of SSDI application.

First-party Special Needs Trust for MS

When someone with MS receives a lump sum in their own name — a personal injury settlement, an inheritance, a disability insurance policy payout that exceeds the SSI resource limit, or an employer settlement — that money creates a Medicaid and SSI eligibility problem. SSI's countable resource limit is $2,000, and Medicaid will be lost if assets exceed the state Medicaid threshold.

A first-party Special Needs Trust (also called a d4A trust under 42 U.S.C. § 1396p(d)(4)(A)) solves this by holding the money in a trust that doesn't count as a resource for SSI or Medicaid. Key rules:

• Must be established while the beneficiary is under age 65. First-party SNTs cannot be created for individuals 65 or older — an urgent planning note for PPMS patients who are diagnosed later in life.
• Must be established by a parent, grandparent, legal guardian, or the court — not by the person with MS themselves (though this is a legal technicality that can typically be accomplished with court approval).
• Medicaid payback provision: At the beneficiary's death, the state Medicaid program must be reimbursed for benefits paid during the beneficiary's lifetime before any remaining funds pass to other heirs.
• Pooled trusts as an alternative: If the first-party d4A trust is unavailable (e.g., over age 65) or the asset amount doesn't justify a standalone trust, a pooled special needs trust — managed by a nonprofit — accepts first-party funds at any age and offers the same SSI/Medicaid protection. See the Pooled Special Needs Trust guide for a detailed comparison.

The first-party SNT should be established before any settlement check is issued or inheritance is received. An attorney who specializes in special needs planning and elder law must draft the trust — the specific statutory language matters for Medicaid compliance.

Third-party Special Needs Trust for MS

When parents, siblings, or other family members want to leave assets to support a family member with MS without destroying SSI/Medicaid eligibility, a third-party SNT is the vehicle. Third-party trusts are funded with the planner's money (not the MS beneficiary's own money), have no Medicaid payback requirement, and can be fully inherited by other family members at the beneficiary's death.

Third-party SNT planning for MS differs from childhood disability planning in that the beneficiary is often:

• Working, or recently stopped working, and may become SSDI-eligible rather than SSI-eligible (in which case SSI's $2,000 resource limit may not be the primary concern for a period)
• Potentially able to receive the inheritance directly if SSDI is the only benefit (SSDI has no resource test) — but will lose SSI and possibly Medicaid if SSI is in the picture
• At risk of qualifying for both SSI and SSDI (concurrent beneficiary) if SSDI benefits are low — in which case the $2,000 resource limit matters again

A specialist advisor will model whether the MS family member will be SSI-only, SSDI-only, or concurrent, and structure the estate plan accordingly. Do not assume that SSDI eliminates the need for SNT planning — in many low-earnings-history cases, both SSDI and SSI benefits coexist.

SNT sizing for progressive MS

SNT sizing for MS is harder than for many other conditions because of the high uncertainty in disease trajectory. A framework:

Scenario 1: RRMS with stable plateau (optimistic)

RRMS patient well-controlled on DMTs with minimal EDSS progression; living independently or with minimal support; SSDI covers basic income; ABLE account covers disability-related expenses; SNT needed primarily for supplemental support if DMTs become unaffordable or care needs increase. Target SNT corpus: $200,000–$500,000 as a supplemental reserve.

Scenario 2: SPMS transition (moderate)

Secondary progressive phase with accumulating disability, increasing personal care needs, possible need for supported living or residential care, DMT costs declining (few effective DMTs for SPMS), but personal care costs rising significantly. SNT must cover personal care attendant hours not funded by HCBS waiver, adaptive equipment, accessible housing modifications, and transportation. Target SNT corpus: $500,000–$1,500,000.

Scenario 3: Advanced progressive MS (full support)

Advanced MS with severe disability requiring full-time personal care; cognitive involvement; unable to live independently; HCBS waiver funding covers basic residential support but SNT fills the gap for a higher quality of life. SNT covers: supplemental personal care hours, accessible vehicle, equipment upgrades, travel to specialist physicians, dental and vision care, recreational and social participation. Without HCBS waiver coverage: the SNT must bear the full cost of supportive care at $35,000–$80,000+ per year. Use the Lifetime Care Cost Projection Calculator to build a year-by-year model, then the SNT Funding Calculator to determine the required trust corpus net of SSDI and expected waiver coverage.

SSI, SSDI, and the MS benefits picture

Benefits eligibility for MS patients depends on work history:

• Substantial work history: SSDI as primary benefit. SSI may or may not apply (only if SSDI benefit is low enough that the combined SSDI + SSI doesn't exceed SSI's income cutoff). SSDI has no resource test — accumulating savings on SSDI alone does not affect benefits.
• Limited work history (recently diagnosed young adult, or adult with gap years): SSI as primary benefit. The $2,000 resource limit applies. ABLE account and SNT are the primary tools for asset protection.
• Concurrent SSDI + SSI: If SSDI is low (e.g., $600/month), SSI tops it up to the FBR of $994/month in 2026, but applies its resource limit and earned-income rules to the combined household. Planning is more complex.

SSI work incentives (earned income exclusion, IRWE, Section 1619(b) Medicaid protection) apply to MS patients receiving SSI. See the SSI Work Incentives 2026 guide for detailed mechanics. Key point for MS patients: Section 1619(b) allows Medicaid to continue even if earnings exceed SSI's SGA threshold — critical for MS patients who return to part-time work and still need Medicaid for DMT coverage.

ABLE account for MS

ABLE accounts work well for MS patients who are on SSI or who have disability-related expenses they want to manage with accessible, beneficiary-controlled funds:

• 2026 annual contribution limit: $20,000 from all sources. Working MS patients can contribute an additional $15,650 from earned income (ABLE-to-Work).⁶
• Age eligibility: Disability onset before age 46 (expanded from 26 by the ABLE Age Adjustment Act, effective January 2026). MS typically presents before age 46, meeting this criterion for most patients.
• SSI protection: up to $100,000 in an ABLE account doesn't count against the $2,000 SSI resource limit.
• Practical use: Accessible transportation costs (Uber/Lyft, accessible vehicle maintenance), DMT copays and medical co-pays, assistive technology (voice-control software, ergonomic equipment for continuing to work), home modifications, and wellness expenses.
• MS patients on SSDI only (no SSI) aren't subject to the $2,000 resource limit, so the ABLE account is less critical for benefit preservation — but still useful for tax-advantaged disability expense savings.

HCBS Medicaid waiver: the long game for MS

Home and Community-Based Services waivers fund personal care attendant hours, home modifications, accessible transportation, day programs, and supportive employment. For MS patients with physical disability, the relevant waiver is typically the physical disability or acquired brain injury waiver (distinct from the intellectual/developmental disability waiver, which requires cognitive impairment as the primary diagnosis).

Physical disability waiver waitlists range from under a year to 5+ years depending on state. The planning principle: apply now, before personal care needs are urgent. Reaching the top of the waitlist when the need is critical is better than applying when the need arrives and waiting years for services. See the HCBS Medicaid Waiver guide for the application framework.

For MS patients with significant cognitive involvement or fatigue-related functional impairment: evaluate whether a combined physical + cognitive waiver is available in your state, as the standard physical disability waiver may not cover the full scope of support needs.

The three-professional team for MS financial planning

1. Fee-only financial advisor specializing in special needs and disability planning: Models the SSDI benefit amount, sizes the income gap between current earnings and SSDI, builds the Medicare gap coverage plan, determines whether life insurance is still obtainable and at what cost, projects SNT funding targets under multiple disease trajectories, and integrates the ABLE account and retirement account strategy. For MS specifically: the advisor should understand the SSDI Medicare waiting period and the impact of DMT costs on cash flow during that gap.
2. Special needs trust attorney: Drafts first-party or third-party SNT with MS-appropriate distribution language. Distribution standards should explicitly authorize DMT co-pays and coverage gaps, neurological specialist visits, experimental treatments, home modifications for increasing physical disability, personal care hours exceeding Medicaid waiver coverage, cognitive rehabilitation, and assistive technology. MS-specific SNT language is meaningfully different from generic SNT language — a specialist attorney who regularly drafts MS SNTs will have this standard language; a general estate attorney may not.
3. SSDI attorney or benefits counselor (CWIC/WIPA): Advises on onset date strategy, file-and-suspend considerations, coordination of SSDI with any employer long-term disability (LTD) policy (private LTD typically offsets against SSDI dollar-for-dollar, requiring plan management), and SSI/SSDI concurrent planning. Available at no cost for SSI recipients through WIPA programs in every state.

Priority actions for MS patients and families

1. Apply for individual disability income insurance immediately after diagnosis, while still working. This is the most time-sensitive action for working-age adults. A disability income policy provides 60–70% of income replacement during a leave of absence or permanent disability — and it is not subject to the SSDI 5-month waiting period or Medicare gap. Once significant disability accumulates, this insurance is unavailable.
2. Assess life insurance options now. If parents plan to fund an SNT for an adult child with MS, evaluate survivorship life insurance on the parents. If the person with MS has dependents, evaluate whether individual life insurance is still accessible. Engage a broker specializing in impaired-risk underwriting.
3. Model the Medicare gap explicitly. If SSDI filing is likely within 3–5 years, calculate when Medicare will begin, the cost of bridging coverage, and the SSDI disability COBRA extension eligibility (up to 29 months). Cash reserves or a short-term disability policy bridge matter here.
4. Establish a first-party SNT framework before any lump sum is received. If a settlement is anticipated — personal injury, employer disability payment, or inheritance directly to the person with MS — the d4A trust must be established before that money arrives. The time to consult an attorney is before the check is issued, not after.
5. Apply for HCBS waiver now, regardless of current disability level. Physical disability waivers have long waitlists. Apply at any stage of MS and move up the list over time.
6. Open an ABLE account if receiving SSI or if the person with MS wants a beneficiary-controlled account for disability expenses. Start contributing even small amounts to build the balance outside the SSI resource limit.
7. Review all beneficiary designations and estate documents through the lens of SNT planning. Direct IRA or 401(k) beneficiary designations to someone with SSI-qualifying MS will destroy Medicaid eligibility. See the Retirement Accounts and Special Needs guide for the correct structures.

Sources

1. National MS Society — How Many People Live With Multiple Sclerosis? Nearly 1 million people in the United States are living with MS, with approximately 200 new diagnoses per week. MS is most commonly diagnosed in adults between ages 20 and 50, with women diagnosed at roughly three times the rate of men. Approximately 2.9 million people have MS globally.
2. SSA — Substantial Gainful Activity and Benefit Rates 2026. SSI Federal Benefit Rate: $994/month for an eligible individual (2026). SSDI SGA: $1,690/month (non-blind). Trial Work Period trigger: $1,210/month. SSDI 5-month waiting period: statutory under Social Security Act § 223(a)(1); no payments for months 1–5 after onset date. Medicare: begins 24 months after first month of SSDI entitlement per SSA POMS SI 01150.005. Values indexed annually to CPI.
3. Multiple Sclerosis News Today — High Medical Costs for MS Patients Starting Ocrevus, Lemtrada, Tysabri. Average total annual medical costs for MS patients initiating Ocrevus: $125,000+ in year 1, ~$110,000 in year 2. Tysabri initiation: $117,000+ year 1. Ocrevus list price approximately $65,000/year; facility infusion markups account for the gap between list and total medical cost. Drug costs are the primary driver of total MS healthcare spending.
4. Medicare.gov — Medicare Before Age 65 (SSDI Beneficiaries). Medicare begins automatically after 24 months of SSDI entitlement. Starting January 1, 2026: Medicare Part D out-of-pocket costs capped at $2,100 per year under the Inflation Reduction Act. Infusion DMTs (Ocrevus, Tysabri) covered under Part B with 20% coinsurance; oral/self-injectable DMTs covered under Part D subject to the $2,100 cap. Medigap supplemental coverage can reduce Part B coinsurance to near zero for infusion DMTs.
5. SSA Blue Book — 11.00 Neurological Disorders (Adult), including Listing 11.09 Multiple Sclerosis. MS evaluated under Listing 11.09: 11.09A (disorganization of motor function in two extremities causing extreme limitation in standing, balancing, or upper extremity use) or 11.09B (marked limitation in physical functioning AND marked limitation in one mental area). RFC-based evaluation available when listing criteria are not met. Listings last updated September 29, 2025.
6. ABLE National Resource Center — 2026 Contribution Limits and Eligibility. Annual ABLE contribution limit: $20,000 from all sources (2026). ABLE-to-Work: working beneficiaries may contribute an additional amount up to the federal poverty level for a one-person household ($15,650 in 2026) from earned income. Age eligibility expanded to disability onset before age 46 effective January 2026 (ABLE Age Adjustment Act). SSI protection: ABLE account balance up to $100,000 does not count toward SSI's $2,000 resource limit.

Rules verified against 2026 SSA, Medicare, and ABLE standards. SSI FBR $994/month (2026). SSDI SGA $1,690/month, TWP trigger $1,210/month (2026). ABLE contribution limit $20,000/year; ABLE-to-Work additional $15,650/year; age eligibility onset before 46 (all 2026). Medicare Part D OOP cap $2,100 (2026, Inflation Reduction Act). Ocrevus and Tysabri total annual cost estimates from 2023 real-world cost study; actual costs vary by facility, insurance, and patient assistance. Disease prevalence from National MS Society (2025). Blue Book Listing 11.09 as of September 2025 update.